Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6542
    +0.0019 (+0.28%)
     

  • OIL

    83.91
    +0.34 (+0.41%)
     

  • GOLD

    2,351.00
    +8.50 (+0.36%)
     

  • Bitcoin AUD

    98,961.73
    +1,407.40 (+1.44%)
     

  • CMC Crypto 200

    1,338.83
    -57.71 (-4.13%)
     

  • AUD/EUR

    0.6112
    +0.0039 (+0.65%)
     

  • AUD/NZD

    1.0986
    +0.0028 (+0.26%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,692.13
    +261.62 (+1.50%)
     

  • FTSE

    8,135.82
    +56.96 (+0.71%)
     

  • Dow Jones

    38,266.40
    +180.60 (+0.47%)
     

  • DAX

    18,161.22
    +243.94 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Baudax Bio, Inc.
·1-min read

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will be made available for on-demand listening beginning Monday, September 13, 2021 at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

ADVERTISEMENT

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com